• Ping-Chuan Liu, Ann-Shung Lieu, Chien-Ju Lin, Hung-Pei Tsai, Chee-Yin Chai, and Aij-Lie Kwan.
• Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
• World Neurosurg. 2021 May 1; 149: e1056e1060e1056-e1060.

BackgroundMeningioma has the second highest incidence among primary intracranial tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. Sp1 (specificity protein 1) is a transcription factor that regulates tumor growth, but the literature describing the relationship between Sp1 and meningioma is scarce. The purpose of this study was to investigate the relationship between Sp1 expression and the clinicopathological parameters in meningioma by immunohistochemical staining.MethodsWe collected samples from 74 patients from 2008-2012 in Kaohsiung Medical University Hospital, with staging and prognosis of the pathological section of the meningioma.ResultsOur results show that Sp1 expression was significantly associated with World Health Organization grade, malignancy, and recurrence in patients with meningioma.ConclusionsHigh expression of Sp1 in patients with meningioma was linked to poor prognosis of recurrence-free time. Therefore Sp1 may be a candidate biomarker of prognosis and therapy target in meningioma.Copyright © 2021 Elsevier Inc. All rights reserved.

34 keywords...

hide…